ENO3 (mouse)

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Protein Page:

ENO3 (mouse)

p	Phosphorylation
a	Acetylation
m	Methylation
m1	Mono-methylation
m2	Di-methylation
m3	Tri-methylation
u	Ubiquitination
s	Sumoylation
n	Neddylation
gl	O-GlcNAc
ga	O-GalNAc
h	Palmitoylation
ad	Adenylylation
sn	S-Nitrosylation
ca	Caspase cleavage

Overview

ENO3 Appears to have a function in striated muscle development and regeneration. Defects in ENO3 are the cause of glycogen storage disease type 13 (GSD13). A metabolic disorder that results in exercise-induced myalgias, generalized muscle weakness and fatigability. It is characterized by increased serum creatine kinase and decreased enolase 3 activity. Dramatically reduced protein levels with focal sarcoplasmic accumulation of glycogen- beta particles are detected on ultrastructural analysis. Belongs to the enolase family. 3 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.

Protein type: EC 4.2.1.11; Carbohydrate Metabolism - glycolysis and gluconeogenesis; Lyase

Cellular Component: phosphopyruvate hydratase complex; membrane; cytoplasm; extracellular region

Molecular Function: protein homodimerization activity; protein heterodimerization activity; metal ion binding; magnesium ion binding; lyase activity; phosphopyruvate hydratase activity

Biological Process: glycolysis

Reference #: P21550 (UniProtKB)

Alt. Names/Synonyms: 2-phospho-D-glycerate hydro-lyase; Beta-enolase; Eno-3; Eno3; ENOB; Enolase 3; enolase 3, beta muscle; MSE; Muscle-specific enolase; OTTMUSP00000006349; OTTMUSP00000006350; Skeletal muscle enolase

Gene Symbols: Eno3

Molecular weight: 47,025 Da

Basal Isoelectric point: 6.73 Predict pI for various phosphorylation states

Select Structure to View Below

	ENO3

Modification Sites and Domains

Show Modification Legend

Click here to view phosphorylation modifications only

Modification Sites in Parent Protein, Orthologs, and Isoforms Show Modification Legend

Show Multiple Sequence Alignment

SS SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.		mouse

0	1	K5-u	___MAMQkIFAREIL
0	1	K28-u	EVDLHTAkGRFRAAV
0	2	S37-p	RFRAAVPsGAstGIy
0	12	S40-p	AAVPsGAstGIyEAL
0	58	T41-p	AVPsGAstGIyEALE
1	1884	Y44-p	sGAstGIyEALELRD
0	1	K54-u	LELRDGDkARYLGKG
0	1	K60	DkARYLGKGVLkAVE
0	2	K64-u	YLGKGVLkAVEHINk
0	1	K71	kAVEHINKTLGPALL
0	1	K71-u	kAVEHINkTLGPALL
0	1	T72	AVEHINkTLGPALLE
0	1	K80-u	LGPALLEkkLsVVDQ
0	2	K81-u	GPALLEkkLsVVDQE
0	3	S83-p	ALLEkkLsVVDQEKV
0	1	K92-u	VDQEKVDkFMIELDG
0	1	K105	DGTENKSKFGANAIL
0	2	Y131	AEKGVPLYRHIADLA
0	1	S176	MILPVGASSFkEAMR
0	1	S177	ILPVGASSFkEAMRI
0	1	K179-a	PVGASSFkEAMRIGA
0	1	K179-u	PVGASSFkEAMRIGA
0	1	Y189	MRIGAEVYHHLKGVI
0	1	K202-u	VIKAKYGkDATNVGD
0	1	Y252	DVAASEFYRNGkYDL
0	1	K256-u	SEFYRNGkYDLDFKs
0	1	Y257	EFYRNGkYDLDFKsP
0	1	K262	GkYDLDFKsPDDPAR
0	4	S263-p	kYDLDFKsPDDPARH
0	3	K275-u	ARHISGEkLGELYKN
0	1	N282	kLGELYKNFIQNYPV
0	1	Y287	YKNFIQNYPVVSIED
0	1	K326-a	DLTVTNPkRIAQAVE
0	4	K326	DLTVTNPKRIAQAVE
0	1	K334-a	RIAQAVEkKACNCLL
0	1	K358	TESIQACKLAQsNGW
0	1	S362-p	QACKLAQsNGWGVMV
0	3	K394-u	GLCTGQIkTGAPCRS
0	1	K420-u	IEEALGDkAVFAGRK

	human

K5	___MAMQKIFAREIL
K28	EVDLHTAKGRFRAAV
S37-p	RFRAAVPsGAstGIy
S40-p	AAVPsGAstGIyEAL
T41-p	AVPsGAstGIyEALE
Y44-p	sGAstGIyEALELRD
K54	LELRDGDKGRYLGkG
K60-a	DKGRYLGkGVLKAVE
K64	YLGkGVLKAVENINs
S71-p	KAVENINstLGPALL
S71	KAVENINStLGPALL
T72-p	AVENINstLGPALLQ
K80	LGPALLQKKLsVADQ
K81	GPALLQKKLsVADQE
S83-p	ALLQKKLsVADQEKV
K92	ADQEKVDKFMIELDG
K105-u	DGTENKSkFGANAIL
Y131-p	AEKGVPLyRHIADLA
S176-p	MILPVGAssFKEAMR
S177-p	ILPVGAssFKEAMRI
K179	PVGAssFKEAMRIGA
K179	PVGAssFKEAMRIGA
Y189-p	MRIGAEVyHHLKGVI
K202	VIKAKYGKDATNVGD
Y252-p	DVAASEFyRNGKyDL
K256	SEFyRNGKyDLDFks
Y257-p	EFyRNGKyDLDFksP
K262-a	GKyDLDFksPDDPAR
S263-p	KyDLDFksPDDPARH
K275-u	ARHITGEkLGELYKs
S282-p	kLGELYKsFIKNyPV
Y287-p	YKsFIKNyPVVSIED
K326	DLTVTNPKRIAQAVE
K326-u	DLTVTNPkRIAQAVE
K334	RIAQAVEKKACNCLL
K358-u	TESIQACkLAQSNGW
S362	QACkLAQSNGWGVMV
K394-u	GLCTGQIkTGAPCRS
K420	IEEALGDKAIFAGRK

	rat

K5	___MAMQKIFAREIL
K28	EVDLHTAKGRFRAAV
S37	RFRAAVPSGAsTGIy
S40-p	AAVPSGAsTGIyEAL
T41	AVPSGAsTGIyEALE
Y44-p	SGAsTGIyEALELRD
K54	LELRDGDKSRYLGKG
K60	DKSRYLGKGVLKAVE
K64	YLGKGVLKAVEHINK
K71	KAVEHINKTLGPALL
K71	KAVEHINKTLGPALL
T72	AVEHINKTLGPALLE
K80	LGPALLEKKLSVVDQ
K81	GPALLEKKLSVVDQE
S83	ALLEKKLSVVDQEKV
K92	VDQEKVDKFMIELDG
K105	DGTENKSKFGANAIL
Y131	AEKGVPLYRHIADLA
S176	MILPVGASSFKEAMR
S177	ILPVGASSFKEAMRI
K179	PVGASSFKEAMRIGA
K179	PVGASSFKEAMRIGA
Y189	MRIGAEVYHHLKGVI
K202	VIKAKYGKDATNVGD
Y252	DVAASEFYRNGKYDL
K256	SEFYRNGKYDLDFKS
Y257	EFYRNGKYDLDFKSP
K262	GKYDLDFKSPDDPAR
S263	KYDLDFKSPDDPARH
K275	ARHISGEKLGELYKS
S282	KLGELYKSFIKNYPV
Y287	YKSFIKNYPVVSIED
K326	DLTVTNPKRIAQAVE
K326	DLTVTNPKRIAQAVE
K334	RIAQAVEKKACNCLL
K358	TESIQACKLAQSNGW
S362	QACKLAQSNGWGVMV
K394	GLCTGQIKTGAPCRS
K420	IEEALGDKAVFAGRK

Home \| Curator Login	With enhanced literature mining using Linguamatics I2E		Produced by 3rd Millennium \| Design by Digizyme
			©2003-2013 Cell Signaling Technology, Inc.